Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
Life Questionnaire (EORTC QLQ-C30), a 30 item questionnaire yielding five
functional scales, three symptom scales, a global health status/QoL scale, and
six single items. Analysis was stratified by patients’ line of therapy. Statistical
significance was assessed using Mann-Whitney U tests. Results: Patients’
mean (SD) age was 65.2 (9.7), 68.8% were male and 89.0% had stage IV NSCLC.
Over two-thirds (71%) of patients were receiving 1st line advanced therapy,
whilst 29% were receiving later lines of therapy. Regarding histology, 74% of
patients were non-squamous compared to 26% squamous. The mean EQ-5D-3L
index for 2 nd line or later patients was significantly lower compared to patients
on 1 st line treatment (0.57 vs 0.65; p=0.002). Three domains showed significant
decreases: mobility, self-care and ability to perform usual activities. In terms of
EORTC scores, patients on later lines of treatment experienced a lower overall
global health status (QL2) compared to 1 st line patients (43.8 vs 50.7; p1. The majority of cases in young group were stage
IIIB (77.3.%). Pathology was squamous (40.9%), adenocarcinoma (22.7%),
undifferentiated (22.7%) and adenosquamous carcinoma in 4.5% of our cases.
Median OS and PFS was 18 and 4 months respectively. Significant difference
in OS and PFS was observed among responder versus non responders in
multivariate analysis (Figure) Conclusion: Good response to chemotherapy is
the best way to prolong survival among young NSCLC cases irrespective of PS,
gender, stage or pathology.
P1.06-034 OUTCOMES AFTER PULMONARY METASTASECTOMY FOR
METASTATIC CANCER
Prakash Balakrishnan 1 , Yousr Al-Sheibani 2 , Sean Galvin 2 , Barry Mahon 2 , John
Riordan 2 , James Mcgiven 2
1 Cardiothoracic Department, Wellington Regional Hospital, Wellington/New
Zealand, 2 Cardiothoracic Surgery, Wellington Hospital, Wellington/New Zealand
Background: In most malignant diseases, the ability to constantly
metastasize remains a truly challenging obstacle in cancer patients.
Historically in the past, any local surgical treatment in patients with systemic
malignant disease is considered without any prognostic benefit, this has
since evolved with many studies confering huge success rates with excellent
prognostic benefits. We hereby report our experience over the last 10 years at
Wellington Regional Hospital, Cardiothoracic unit. Methods: A retrospective
study was undertaken in series of patients with colorectal, melanoma, breast,
sarcoma & renal metastatic disease undergoing pulmonary metastasectomy,
from year 2000 to 2010. These data was identified & stratified into groups
using hospital patient database & ORSOS theatre database with the aid
of Excel spreadsheet. Results: All these patients were operated on either
– unilateral versus bilateral, VATS or thoracotomies with or without lymph
node dssection as well as repeat surgeries. The role of metastatectomy in
their treatment options & the prognostic factors with impact on survival
discussed. Conclusion: In carefully selected surgical patients, pulmonary
metastasectomy for metastatic diseases confers continual prognostic &
survival advantage for these patients.
Keywords: pulmonary metastasectomy, Metastatic Disease, outcomes
POSTER SESSION 1 - P1.06: ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/
IMMUNOTHERAPY
ADVANCED GENERAL –
MONDAY, DECEMBER 5, 2016
P1.06-035 FREQUENCY AND CLINICAL RELEVANCE OF
EGFR-MUTATIONS AND EML4-ALK-TRANSLOCATIONS IN
OCTAGENARIANS WITH NSCLC
Amanda Tufman 1 , Simone Reu 2 , Sandra Hasmann 3 , Diego Kauffmann-
Guerrero 1 , Katrin Milger 1 , Zulfiya Syunyaeva 1 , Kathrin Kahnert 1 , Rudolf Huber 1
1 Respirology and Thoracic Oncology, Comprehensive Pneumology Center, Member
of the German Center for Lung Research Dzl, Ludwig Maximilian University of
Munich, Munich/Germany, 2 Institute of Pathology, Ludwig-Maximilians University,
Munich/Germany, 3 Ludwig-Maximilians University Munich, Munich/Germany
Background: Novel therapies targeting genetic alterations have improved
response rates and overall survival for some patients with NSCLC;
however, only a minority of caucasian patients with lung cancer benefit
from these treatments. Testing for EGFR mutation and ALK translocation
is recommended for all patients with advanced adenocarcinoma, but
the highest occurance of these driver mutations has been described in
S354 Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017